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Abstract
BACKGROUND—Genetic variability among patients plays an important role in determining the
dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods
of using genetic information have not been evaluated in a diverse and large population. We
developed and used an algorithm for estimating the appropriate warfarin dose that is based on both
clinical and genetic data from a broad population base.
METHODS—Clinical and genetic data from 4043 patients were used to create a dose algorithm
that was based on clinical variables only and an algorithm in which genetic information was added
to the clinical variables. In a validation cohort of 1009 subjects, we evaluated the potential clinical
value of each algorithm by calculating the percentage of patients whose predicted dose of warfarin
was within 20% of the actual stable therapeutic dose; we also evaluated other clinically relevant
indicators.
RESULTS—In the validation cohort, the pharmacogenetic algorithm accurately identified larger
proportions of patients who required 21 mg of warfarin or less per week and of those who required
49 mg or more per week to achieve the target international normalized ratio than did the clinical
algorithm (49.4% vs. 33.3%, P<0.001, among patients requiring ≤21 mg per week; and 24.8% vs.
7.2%, P<0.001, among those requiring ≥49 mg per week).
CONCLUSIONS—The use of a pharmacogenetic algorithm for estimating the appropriate initial
dose of warfarin produces recommendations that are significantly closer to the required stable
therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach. The
greatest benefits were observed in the 46.2% of the population that required 21 mg or less of
warfarin per week or 49 mg or more per week for therapeutic anticoagulation.
Warfarin is the most widely used oral anticoagulant agent worldwide; more than 30 million
prescriptions were written for this drug in the United States in 2004.1 The appropriate dose
of warfarin is difficult to establish because it can vary by a factor of 10 among patients, and
the consequences of taking an incorrect dose can be catastrophic. Because incorrect doses
contribute to a high rate of adverse effects, there is interest in developing improved
strategies for determining the appropriate dose.2
Clinical factors, demographic variables, and variations in two genes — cytochrome P450,
family 2, subfamily C, polypeptide 9 (CYP2C9), and vitamin K epoxide reductase complex,
subunit 1 (VKORC1) — contribute significantly to the variability among patients in dose
requirements for warfarin.3-18 In 2007, the Food and Drug Administration added
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pharmacogenetic information to the warfarin product label19 but did not propose a specific
method for using genetic information to predict the dose required in individual patients.
Proposed algorithms for predicting the appropriate dose of warfarin3,5,9,13,18,20 are
usually based on relatively small clinical populations, and their general predictive accuracy
is uncertain.21 Small trials have recently been performed3,22 and large, prospective trials
are ongoing or planned in the United States23 and Europe to test whether algorithms for
warfarin dosage that use genetic information improve the outcomes for patients (e.g., better
anticoagulation control and a shorter time to achieving a stable dose). We developed a
pharmacogenetic dose algorithm for warfarin with the use of a large and diverse data set that
included data from patients at centers around the world and used it to determine
retrospectively whether the dosage recommendations that were based on this algorithm were
significantly better than those that were based on an algorithm that used only clinical
variables or those that were based on a fixed-dose strategy.
METHODS
DATA COLLECTION AND STUDY COHORTS
The International Warfarin Pharmacogenetics Consortium comprises 21 research groups
from 9 countries and 4 continents. The research groups contributed clinical and genetic data
for a total of 5700 patients who were treated with warfarin. These data were curated (i.e.,
collected, formatted, and subjected to quality control) by staff at the Pharmacogenetics and
Pharmacogenomics Knowledge Base (PharmGKB, www.pharmgkb.org) and by members of
the consortium. The cohort whose data were analyzed for this study included the subgroup
of 5052 patients who had a target international normalized ratio (INR) of 2 to 3. The
requirement for informed consent was waived because consent had been obtained previously
by each participating center, and only de-identified data were used in the study.
We collected data on clinical factors that have previously been associated with warfarin
therapy and that were available from the information received from all or most sites. These
data included information on demographic characteristics, the primary indication for
warfarin treatment, the stable therapeutic dose of warfarin, the treatment INR (the INR
achieved with a stable warfarin dose), the target INR (the desired INR), the use of
concomitant medications (grouped according to those that increase and those that decrease
the INR), and the presence of genotype variants of CYP2C9 (*1, *2 and *3) and VKORC1
(at least one of seven single nucleotide polymorphisms [SNPs] in linkage disequilibrium11),
as detailed in Section 1 in Supplementary Appendix 1, available with the full text of this
article at NEJM.org. Information on race or ethnic group was reported by the patient or
determined by the local investigator. Several potentially important variables (e.g., vitamin K
intake and smoking status) were not consistently available and thus were not included. Data
on adverse events such as thromboembolic events or bleeding or the need for repeated
measurements of the INR before a stable dose was achieved were not available for this
study. The outcome variable was the stable therapeutic dose of warfarin, defined as the
steady-state dose that led to stable anticoagulation levels. Although the centers used
different definitions for steady-state dose, most centers required stable levels of
anticoagulation (i.e., INR) over a period during which the dose of warfarin was stable
(Section 2 in Supplementary Appendix 1).
GENOTYPE QUALITY CONTROL
The National Genotyping Center at the Institute of Biomedical Sciences, Academia Sinica,
Taipei, Taiwan, performed blinded regenotyping for quality control on DNA samples from
10% of the subjects from each site (except for sites 3, 9, and 14, which could not ship DNA
samples internationally). DNA samples that were used for quality control were genotyped
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for the two polymorphisms in CYP2C9 (*2=rs1799853, and *3=rs1057910) and seven SNPs
in VKORC1 (−1639 G→A=rs9923231, 1173 C→T=rs9934438, 497 T→G=rs2884737,
1542 G→C=rs8050894, 3730 G→A=rs7294, 2255 C→T=rs2359612, −4451
C→A=rs17880887). CYP2C9 *2 and *3 and VKORC1 rs9923231 were genotyped with the
use of the TaqMan allelic discrimination assay (Applied Biosystems), whereas the
remaining VKORC1 SNPs were genotyped by mass spectrometry with the use of
MassARRAY (Sequenom). Both methods had been validated previously at the National
Genotyping Center with the use of direct sequencing and denaturing high-performance
liquid chromatography, with 100% concordance on 200 samples. The complete data set of
genotypes and clinical variables, as well as the full genotype quality-control data, is
available to registered PharmGKB users at www.pharmgkb.org (full data set accession
number, PA162355460).
STATISTICAL ANALYSIS
We randomly chose 80% of the eligible patients, (stratified according to site, for a total of
4043 patients who had a stable dose of warfarin and a target INR of 2 to 3) as the
“derivation cohort” for developing all dose-prediction models. The remaining 20% of the
patients (1009 patients, from all 21 sites) constituted the “validation cohort,” which was
used for testing the final selected model. The investigators who performed the modeling and
analysis did not have access to this validation set until after the final model was selected. A
wide variety of numerical modeling methods were used for the data from the derivation
cohort, including, but not limited to, support vector regression, regression trees, model trees,
multivariate adaptive regression splines, least-angle regression, and Lasso, in addition to
ordinary linear regression. Logarithmic and square-root transformations of doses were
tested, in addition to a direct prediction of dose. Further details of the statistical modeling
approaches that were tested and the evaluation methods that were used for selecting the best
model from the derivation cohort are described in Section 3 in Supplementary Appendix 1.
Missing values for the VKORC1 SNP rs9923231 were imputed on the basis of race and on
the basis of the VKORC1 SNP data at rs2359612, rs9934438, or rs8050894 (see Section 4 in
Supplementary Appendix 1). If the VKORC1 genotype could not be imputed, it was treated
as “missing” (a distinct variable) in the model.
The mean absolute error — that is, the mean of the absolute values for the difference
between the predicted and actual maintenance doses — was used to evaluate each model's
predictive accuracy. For models developed with the use of transformed data, the mean
absolute error was computed in the original units rather than in the transformed units to
allow a fair comparison of all models. We selected the final model as the one that had the
lowest predictive mean absolute error as estimated by 10-fold cross-validation on the
derivation cohort (detailed in Section 3 in Supplementary Appendix 1). Using the validation
data set, we compared dose predictions from the pharmacogenetic model with those from
two other models: a clinical model that did not include genetic factors and a model with a
fixed dose of 5 mg of warfarin per day. The clinical model was built with the use of the
same methods as the pharmacogenetic model, but without the incorporation of genetic
variables. The following assessment of clinical significance is based on this validation data
set except where otherwise stated.
The mean absolute error and the coefficient of determination (R2) in the validation data set
were our prespecified metrics for evaluating the pharmacogenetic, clinical, and fixed-dose
models. These models were selected before the metrics were computed; thus, there were no
multiple comparisons. We evaluated the potential clinical value of each algorithm by
calculating the percentage of patients whose predicted dose of warfarin was within 20% of
the actual stable therapeutic dose. In addition, we calculated the percentage of patients for
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whom the predicted dose according to each algorithm was at least 20% higher than the
actual dose (overestimation) or at least 20% lower than the actual dose (underestimation).
These values represent a difference of 1 mg per day relative to the traditional starting dose
of 5 mg per day, a difference clinicians would be likely to define as clinically relevant. We
also assessed the performance of the algorithms in three dose groups: participants requiring
a low dose (≤21 mg per week), those requiring a high dose (≥49 mg per week), and those
requiring intermediate doses (>21 and <49 mg per week) for stable therapeutic
anticoagulation. These thresholds of 21 mg and 49 mg per week bracket the usual starting
dose of 35 mg per week (5 mg per day). Patients requiring doses of less than 21 mg per
week would be at risk for excessive anticoagulation if they were started on the standard dose
of 35 mg per week. Conversely, patients requiring doses of more than 49 mg per week
would be at risk for inadequate anticoagulation if they were started on a dose of 35 mg per
week. We performed sensitivity analyses using other dose thresholds as well (see Section 5
in Supplementary Appendix 1). We assessed the potential benefit of using the
pharmacogenetic algorithm instead of the clinical algorithm or the fixed-dose model and
computed the number needed to genotype (i.e., the number of patients who must be
genotyped in order for one patient to have an improved dose estimate).24 Finally, in a post
hoc analysis, we assessed how well the algorithms predicted which patients actually required
low or high doses.
RESULTS
CHARACTERISTICS OF THE PATIENTS AND QUALITY OF GENOTYPING DATA
The characteristics of the patients are shown in Table 1. Genotype quality control was
conducted on 480 samples (8.4% of the data set). The overall concordance for CYP2C9
SNPs in the genotype quality control was 97.8%, and the overall concordance for VKORC1
SNPs was 97.7%. Exclusion of the three sites that did not participate in the quality-control
genotyping did not change the model. Each SNP was in Hardy–Weinberg equilibrium when
it was tested in patients who were stratified according to race.
MODELING APPROACHES
An ordinary least-squares linear regression modeling method to develop a pharmacogenetic
algorithm that predicts the square root of the dose and incorporates both genetic and clinical
data proved to be the best modeling approach for these data (see Section 3 in Supplementary
Appendix 1; the actual model is shown in Section 1 in Supplementary Appendix 1). This
approach performed best according to our criterion of the lowest mean absolute error but
would also have been selected if the criterion had been the lowest root mean squared error.
Although it may be somewhat surprising that ordinary least-squares regression would
perform best according to the mean absolute error, the reason, in part, appears to be that
minimizing the squared error in the prediction of the square root of the dose effectively
minimizes the mean absolute error. This strong performance of ordinary least-squares
regression was fortuitous because it yielded a simpler and more easily understood model
than many of the more complex modeling approaches we used. Because the resulting dose
algorithm computes the square root of the weekly dose, the output must be squared to
compute the weekly dose. This algorithm is available at www.warfarindosing.org and as a
Microsoft Excel workbook (see Supplementary Appendix 2 and Section 6 in Supplementary
Appendix 1). With the use of the same linear regression approach, we also constructed an
algorithm that included clinical variables only, with no incorporation of genetic data (see
Section 1 in Supplementary Appendix 1).
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DOSES PREDICTED BY THE THREE MODELS
The performance of the pharmacogenetic, clinical, and fixed-dose models in the derivation
and validation cohorts is shown in Table 2. The pharmacogenetic algorithm provided dose
estimates that were significantly closer to the actual doses required than the estimates
derived from the clinical algorithm or the fixed-dose approach, as evidenced by a mean
absolute error that was lower than that for both the clinical algorithm and the fixed-dose
approach (8.5±1.7 mg per week vs. 9.9±1.9 mg per week and 13.0±2.3 mg per week,
respectively; P<0.001 for both comparisons). Figure 1 shows comparisons of the predicted
doses according to representative clinical or demographic characteristics, genotype
combinations, race, and use or nonuse of amiodarone (an important interacting drug). These
data show the way in which the addition of genetic information altered the dose prediction
from the clinical model and suggest that most of the racial differences in dose requirements
are explained by genotype. The addition of genetic information to clinical information
decreased the absolute error in the dose estimate and increased the fraction of variability
explained (R2). The R2 values and the P values for each factor in the two models are shown
in Section 7 in Supplementary Appendix 1; a graph of the predicted warfarin dose based on
the pharmacogenetic algorithm as compared with the observed dose in the validation cohort
is shown in Section 8 in Supplementary Appendix 1.
We also derived specific models for different racial and ethnic groups, but in all cases, the
general model that was adjusted for race performed better than these specific models. The
performance at individual centers reflected the racial and ethnic makeup of the local patient
population, with no influential outliers, a finding that was consistent with the genotype
quality-control data. The pharmacogenetic model performed well for each of the three major
ethnic groups and for each of the 21 sites (Section 9 in Supplementary Appendix 1).
CLINICAL RELEVANCE
The pharmacogenetic algorithm provided more accurate dose estimates than the clinical
algorithm or the fixed-dose approach (Table 2). The differences in the performance of the
three approaches in the low-dose (≤21 mg per week), intermediate-dose (>21 and <49 mg
per week), and high-dose (≥49 mg per week) groups are shown in Figure 2 and Table 3. For
patients who required 21 mg or less of warfarin per week (33.9% of the total cohort), the
pharmacogenetic algorithm provided a significantly better prediction of dose than the
clinical algorithm or the fixed-dose approach; 35% of the dose predictions fell within 20%
of the actual dose (“ideal dose”) with the pharmacogenetic algorithm as compared with 24%
with the clinical algorithm (P<0.001) and 0% with the fixed-dose approach (P<0.001). In
addition, the pharmacogenetic algorithm provided significantly fewer overestimations of
dose in the low-dose group (59.7%, vs. 74.8% with the clinical algorithm [P<0.001]; and
100% with the fixed-dose approach [P<0.001]) (Table 3). Similarly, for patients requiring 49
mg or more per week (12.4% of the total cohort), the pharmacogenetic algorithm predicted
doses in the ideal range for significantly more patients than did the clinical algorithm or the
fixed-dose approach (32.8% vs. 13.3% and 0%, respectively; P<0.001 for both
comparisons), with significantly fewer dose underestimations (66.7% vs. 86.2% and 100%,
respectively; P<0.001 for both comparisons). In the intermediate-dose group, the accuracy
of the dose prediction was similar with the three approaches. A sensitivity analysis that used
different dose thresholds (Section 5 in Supplementary Appendix 1) highlighted the fact that
the pharmacogenetic algorithm provided consistently better dose prediction. Table 4 shows
the comparison of the pharmacogenetic and clinical algorithms with respect to dose
prediction for patients who required low or high doses — an important feature for clinicians
when they are initiating treatment. Specifically, for the overall cohort, the pharmacogenetic
algorithm correctly predicted low doses for 54% of all patients who required low doses, as
compared with the clinical algorithm, which predicted low doses for 33% of these patients
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(P<0.001). Similarly, the pharmacogenetic algorithm accurately predicted high doses for
26% of patients who required high doses, as compared with the clinical algorithm, which
predicted high doses for 9% of these patients (P<0.001). Thus, the pharmacogenetic
algorithm significantly improved the dose prediction for patients who required either high or
low doses of warfarin, a group that accounted for 46% of the entire cohort.
Overall, estimates of dose derived with the use of the pharmacogenetic algorithm were
closer to the actual dose than were estimates derived from the clinical algorithm for 60% of
the patients and were closer than the fixed dose for 69% of the patients. To estimate the
potential for a clinically meaningful improvement in dose prediction, we assessed the
number of patients for whom one algorithm estimated a dose within 20% of the actual dose
and the other algorithm did not — a stricter standard than simply the proximity to the actual
dose. For the entire cohort, the number of patients needed to genotype in order to obtain
such an improvement with the pharmacogenetic algorithm in one patient was 13.2 for the
comparison with the clinical algorithm and 6.0 for the comparison with a fixed dose of 35
mg per week (Section 10 in Supplementary Appendix 1).
DISCUSSION
The pharmacogenetic algorithm we developed provided significantly better predictions of
the appropriate dose of warfarin than either the clinical algorithm or a fixed-dose approach.
The greatest differences among the dose-prediction approaches were noted among patients
whose stable therapeutic warfarin doses were 21 mg or less per week and among those
whose stable doses were 49 mg or more per week, representing 46% of the cohort. These are
the patients for whom an underdose or an overdose could have adverse clinical
consequences. Patients who require intermediate doses are likely to obtain little benefit from
the use of a pharmacogenetic algorithm.
Our analysis does not address the issue of whether a precise initial dose of warfarin
translates into improved clinical end points, such as a reduction in the time needed to
achieve a stable therapeutic INR, fewer INRs that are out of range, and a reduced incidence
of bleeding or thromboembolic events. However, our study lays important groundwork for a
prospective trial and suggests that such a trial should be powered to detect the benefits of
incorporating pharmacogenetic information into the dose algorithm for patients who require
high or low doses — the subgroups in our study for whom dose estimates based on the
pharmacogenetic algorithm differed significantly from those based on the clinical algorithm.
Visual inspection of the graph of pharmacogenetic dose prediction as compared with actual
warfarin dose (Section 8 in Supplementary Appendix 1) suggests that the pharmacogenetic
algorithm performed less predictably among patients who required very high doses of
warfarin (>70 mg per week). The common genetic markers explored in our study primarily
explain increased sensitivity to warfarin, not increased resistance. Mutations of VKORC1
have been associated with resistance to warfarin, but these mutations are rare except in
Ethiopian and certain Jewish populations.19,25-28 The discovery of additional genes (e.g.,
through genomewide association studies) may identify additional genetic variants that can
improve predictability in patients who require high doses of warfarin.
Our study has other limitations. First, we did not have sufficient data across the 21 research
groups to include potentially important factors such as smoking status, vitamin K intake, or
alcohol consumption, as well as other genetic factors (e.g., cytochrome P450, family 4,
subfamily F, polypeptide 2 [CYP4F2], apolipoprotein E [ApoE], or gamma-glutamyl
carboxylase [GGCX])4,5,16,17,29-31 or environmental factors32 that could help predict the
stable therapeutic dose of warfarin. However, the percentage of dose variability among
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patients that is explained by our model is similar to that in other published models, so the
effect of these variables is probably small. Second, we did not have any information about
adverse events that may have occurred before stable anticoagulation was achieved; our data
set provided only the eventual stable therapeutic doses. Third, different sites genotyped
different subgroups of VKORC1 SNPs, requiring us to impute missing genotypes for some
patients. Our imputation strategy, which is based on linkage disequilibrium in VKORC1, is
generally reliable (see Section 4 in Supplementary Appendix 1),11 but it may have
introduced some error; however, the error would probably have led to an underestimation of
the benefit of adding genetic information. We also restricted our algorithm to patients who
had a target INR of 2 to 3, so it provides no explicit guidance on dosage to achieve INRs
outside this range. The population included in this study represents the typical population
that is treated with warfarin — namely, the elderly. Only 6% of the cohort was younger than
40 years of age; therefore, additional research with respect to the use of these algorithms in
children and younger adults is needed.
In conclusion, using data from a large and diverse cohort of patients, we developed a
pharmacogenetic dose algorithm for warfarin that uses genotypes from two genes (VKORC1
and CYP2C9) and clinical variables to predict the stable therapeutic dose. This
pharmacogenetic algorithm predicts the stable therapeutic dose of warfarin better than a
fixed-dose approach and better than a clinical algorithm built from the same large data set.
With the use of this algorithm and a definition of the ideal estimated dose as a dose that
differs by no more than 20% from the stable dose, the pharmacogenetic algorithm produced
significantly better dose estimates, with the greatest benefit seen in patients ultimately
requiring 21 mg or less of warfarin per week and in those requiring 49 mg or more per week.
The pharmacogenetic algorithm thus provides a robust basis for a prospective clinical trial of
the efficacy of genetically informed dose estimation for patients who require warfarin.
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Figure 1. Comparisons of Warfarin Doses Predicted According to the Clinical Algorithm and the
Pharmacogenetic Algorithm
Panel A shows the comparisons based on genotype and on use or nonuse of amiodarone.
This example of a 50-year-old non-Asian, nonblack patient who is 1.75 m tall and weighs 80
kg shows that genotype can markedly change the recommended dose from more than 45 mg
per week to less than 10 mg per week when all other factors are the same. Panel B shows the
comparison based on race and genotype. This example of a 50-year-old patient who is 1.75
m tall and weighs 80 kg shows that racial differences in the estimated dose become
insignificant when genetic information is added to the model and that the clinical algorithm,
as compared with the pharmacogenetic algorithm, often produces an average value that may
substantially overestimate or underestimate the dose.
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Figure 2. Percentage of Patients with Dose Estimates within 20% of the Actual Dose, as Derived
with the Use of a Pharmacogenetic Algorithm, a Clinical Algorithm, and a Fixed-Dose Approach
The dose estimates are shown according to three actual-dose groups: low-dose (≤21 mg per
week), intermediate-dose (>21 to <49 mg per week), and high-dose (≥49 mg per week). The
fixed dose was 35 mg per week. With the fixed-dose approach, none of the estimates for the
patients in the low-dose and high-dose groups were within 20% of the actual dose. Panel A
shows data for the validation cohort (1009 patients), and Panel B for the derivation-plus-
validation cohorts (5052 patients).
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(N = 1009) P Value*
Warfarin dose — mg/wk 0.40
 Median 28.0 28.0
 Interquartile range 19.0–38.5 21.0–38.5
Genotype — no. (%)
 VKORC1 rs9923231 0.97
  G/G 1201 (29.7) 302 (29.9)
  A/G 1444 (35.7) 363 (36.0)
  A/A 1315 (32.5) 326 (32.3)
  Unknown 83 (2.1) 18 (1.8)
          CYP2C9 † 0.38
  *1/*1 2970 (73.5) 749 (74.2)
  *1/*2 509 (12.6) 142 (14.1)
  *1/*3 374 (9.3) 76 (7.5)
  *2/*2 36 (0.9) 10 (1.0)
  *2/*3 52 (1.3) 10 (1.0)
  *3/*3 15 (0.4) 1 (0.1)
  Unknown 87 (2.2) 21 (2.1)
Age — no. (%) 0.88
 10–19 yr 11 (0.3) 1 (0.1)
 20–29 yr 80 (2.0) 18 (1.8)
 30–39 yr 145 (3.6) 43 (4.3)
 40–49 yr 363 (9.0) 101 (10.0)
 50–59 yr 753 (18.6) 189 (18.7)
 60–69 yr 1016 (25.1) 239 (23.7)
 70–79 yr 1151 (28.5) 289 (28.6)
 80–89 yr 497 (12.3) 124 (12.3)
 ≥90 yr 27 (0.7) 5 (0.5)
Height — m 0.79
 Median 1.68 1.68
 Interquartile range 1.60–1.76 1.60–1.76
Weight — kg 0.52
 Median 75.3 75.4
 Interquartile range 62.0–89.4 63.0–90.0
Race — no. (%)‡ 0.68
 White 2233 (55.2) 562 (55.7)
 Asian 1229 (30.4) 300 (29.7)
 Black 353 (8.7) 97 (9.6)
 Mixed, or missing data 228 (5.6) 50 (5.0)


















(N = 1009) P Value*
Use of enzyme inducers — no. (%)§ 41 (1.0) 7 (0.7) 0.35
Use of amiodarone — no. (%) 176 (4.4) 56 (5.6) 0.10
*
P values for the difference between the derivation and validation cohorts were calculated with the use of the Wilcoxon rank-sum test (for warfarin
dose, height, and weight), Fisher's exact test (for VKORC1 rs9923231 genotype, CYP2C9 genotype, age, and race), and the z test for proportions
(for use of enzyme inducers and use of amiodarone).
†
The CYP2C9 genotype is designated with the usual * designation; only *2 (rs1799853) and *3 (rs1057910) were considered. Participants who
were homozygous for major alleles at both sites are designated as *1/*1. See www.pharmgkb.org/do/serve?
objId=PA134733494&objCls=NamedAllele for more information.
‡
Information on race was reported by the patient or determined by the local investigator. In some cases, information on race was missing because
the terms were not relevant in the population in which the data were collected.
§
Cytochrome P450 enzyme inducers that were considered in this analysis included phenytoin, carbamazepine, and rifampin.















Predicted Warfarin Doses with the Pharmacogenetic Algorithm, Clinical Algorithm, and Fixed-Dose
Approach as Compared with the Actual Stable Dose in the Derivation and Validation Cohorts.*









Pharmacogenetic algorithm‡§ 8.3±1.7 47 8.5±1.7 43
Clinical algorithm§ 10.0±2.0 27 9.9±1.9 26
Fixed-dose approach¶ 13.3±2.4 0 13.0±2.3 0
*
Plus–minus values are means ±SE. R2 is the coefficient of determination.
†
In the calculation of the mean absolute error in the validation cohort, data from one patient who was taking an unusually high dose of warfarin
were excluded. For details, see Section 11 in Supplementary Appendix 1.
‡
P<0.001 for the pharmacogenetic algorithm as compared with the clinical algorithm, as derived with the use of McNemar's test of paired
proportions.
§
P<0.001 for the pharmacogenetic algorithm as compared with the fixed-dose approach and for the clinical algorithm as compared with the fixed-
dose approach, as derived with the use of McNemar's test of paired proportions.
¶
The fixed dose was 35 mg of warfarin per week.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Ability of the Pharmacogenetic and Clinical Algorithms to Correctly Identify Patients Requiring Low or High
Doses of Warfarin.
Actual or Predicted Dose
Group
≤21 mg/wk ≥49 mg/wk
Pharmacogenetic Algorithm Clinical Algorithm Pharmacogenetic Algorithm Clinical Algorithm
Validation cohort
No. of patients predicted to
require extreme dose
232 162 48 15
No. of patients actually
requiring extreme dose
324 324 125 125
No. of patients correctly
predicted to require extreme
dose
160* 108 31* 9
Percent of patients correctly
predicted to require extreme
dose†
49.4 33.3 24.8 7.2
Derivation-plus-validation cohort
No. of patients predicted to
require extreme dose
1250 829 243 98
No. of patients actually
requiring extreme dose
1711 1711 625 625
No. of patients correctly
predicted to require extreme
dose
929* 571 165 57
Percent of patients correctly
predicted to require extreme
dose†
54.3 33.4 26.4 9.1
*
P<0.001 for the comparison of the pharmacogenetic algorithm with the clinical algorithm, with the use of a two-tailed sign test.
†
This value represents the number of patients correctly predicted to require the extreme dose divided by the number of patients who actually
required the extreme dose.
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